Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: A comparative study with olanzapine

Journal of Psychopharmacology

Volumn 16, Issue 3, 2002, Pages 200-206

  Schmitt, G J E ^a   Meisenzahl, E M ^a   Dresel, S ^a   Tatsch, K ^a   Rossmuller, B ^a   Frodl, T ^a   Preuss, U W ^a   Hahn, K ^a   Moller, H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

123I IBZM; Atypical neuroleptics; Dopamine D2 receptor; Olanzapine; Risperidone; SPECT

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOXEPIN; HALOPERIDOL; IODOBENZAMIDE I 123; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRACER; UNCLASSIFIED DRUG; ZIPRASIDONE; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PIRENZEPINE; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE RECEPTOR BLOCKING; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; FEMALE; HOSPITAL PATIENT; HUMAN; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COMPARATIVE STUDY; DRUG ANTAGONISM; EVALUATION; METABOLISM; MIDDLE AGED; PSYCHOSIS; SCINTISCANNING;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BENZODIAZEPINES; CONTRAST MEDIA; CORPUS STRIATUM; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHOTIC DISORDERS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036708608     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110201600302     Document Type: Article

References (42)

1. Differentiation of classical and novel antipsychotics using animal models
2. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
3. Double-blind olanzapine versus haloperidol D2 dopamine receptor blockade in schizophrenic patients: A baseline-endpoint
4. 123I-IBZM single photon emission tomography (SPET) study
5. Radioreceptor binding profile of the atypical antipsychotic olanzapine
6. 2 receptor occupancy in risperidone-treated schizophrenic patients
7. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamin-induced alterations in regional brain metabolism
8. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine
9. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients
10. New antipsychotics: The present status
11. Treatment of schizophrenia
12. A new framework for investigating antipsychotic action in humans: Lessons from PET imaging
13. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis
14. 2 receptor occupancy and plama levels on low dose oral haloperidol: A PET study
15. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
16. 2 receptor occupancy of clozapiffe, risperidone, and olanzapine in schizophrenia
17. 123I-IBZM SPECT study
18. 2 receptor occupancy in vivo and response to the new antipsychotic risperidone
19. Striatal dopamine D-2 receptor occupancy in psychotic patients treated with risperidone
20. 2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia
21. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
22. Risperidone in the treatment of schizophrenia
23. D2 receptor occupancy under recommended and high doses of olanzapine: An iodine-123-Iodobenzamide SPECT study
24. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values
25. Risperidone in the treatment of schizophrenia: Results of a study of patients from Germany, Austria, and Switzerland
26. Non-equipotent doses partly explain differences among antipsychotics - Implications of PET-studies
27. A PET-study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects
28. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients
29. Risperidone in the treatment of chronic schizophrenic patients: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
30. 123I IBZM single photon emission tomography (SPECT) study
31. 2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET
32. Preclinical pharmacology of neuroleptics: Focus on new generation compounds
33. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
34. Antipsychotic drugs which elict little or no parkinsonism bind more looseley than dopamine to brain D2 receptors, yet occupy high levels of these receptors
35. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
36. Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the D2 or D4 receptor varies with the affinity of the competing radioligand
37. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
38. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
39. Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
40. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
41. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
42. Implications of normal brain development for the pathogenesis of schizophrenia